Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.

You need to replace the power core because someone stole it and left the city powerless. Take the power core and give it to Merchant Hamza. Head back to Sandip. There are a few clues inside that will ...

STEP is here to support your academic journey, especially in your first years at UW. We want to see you reach your goals by focusing on reinfording course material, enhancing study techniques, and ...